Innate Pharma SA business relationships
Companies named in Innate Pharma SA’s 20-F filed 2026-04-01, and public companies whose annual reports name Innate Pharma SA. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 55% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in Innate Pharma SA’s annual report 7
“The Company may terminate the CD39 Potential License Agreement if AstraZeneca challenges any patent licensed to it under the agreement.” SEC filing
“License agreement with Takeda signed in 2023” SEC filing
“• the initiation, timing, progress and results of the Company's preclinical studies and clinical trials and those conducted by third parties, including the Company's collaborators, AstraZeneca and Sanofi;” SEC filing
“The agreement with Novo Nordisk A/S included a right to additional consideration in the event of an out-licensing agreement.” SEC filing
“In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to avdoralimab.” SEC filing
“Under the terms of the license agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration.” SEC filing
“A multi-specific is also being developed in partnership with Sanofi (IPH62).” SEC filing
Companies whose annual reports name Innate Pharma SA 1
“• Innate Pharma SA (2022) : an expanded collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.